Artesunate rectal - Cipla/Medicines for Malaria Venture/Strides

Drug Profile

Artesunate rectal - Cipla/Medicines for Malaria Venture/Strides

Latest Information Update: 26 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator World Health Organization
  • Class 3-ring heterocyclic compounds; Antimalarials; Artemisinins; Small molecules; Succinates
  • Mechanism of Action Free radical stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Malaria

Most Recent Events

  • 01 Dec 2015 Cipla and Strides submit Artesunate rectal for pre-qualification review to the WHO (MMV pipeline - May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top